Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1201086 | 0.89 | TSHR (0.35) | TSHRKDM4ELMNAFFAR1L3MBTL1 | |
| SCHEMBL1199474 | 0.85 | CYP2D6 (0.35) | TSHRKDM4ELMNAFFAR1MAOB | |
| SCHEMBL1199752 | 0.82 | FFAR1 (0.39) | TSHRKDM4EFFAR1ARMAOB | |
| SCHEMBL1200700 | 0.82 | MAOB (0.39) | TSHRKDM4ELMNAFFAR1L3MBTL1 | |
| SCHEMBL1200589 | 0.81 | SCN8A (0.40) | TSHRFFAR1SCN8AARMAOB | |
| SCHEMBL1201102 | 0.80 | AR (0.37) | TSHRKDM4ELMNAFFAR1AR | |
| SCHEMBL1200371 | 0.80 | AR (0.34) | TSHRKDM4EFFAR1SCN8AAR | |
| SCHEMBL1200733 | 0.78 | KMT2A (0.41) | TSHRKDM4EMAOBMEN1KMT2A | |
| SCHEMBL1201055 | 0.77 | TSHR (0.36) | TSHRLMNAFFAR1SCN8AMEN1 | |
| SCHEMBL15375561 | 0.77 | TSHR (0.42) | TSHRLMNASCN8AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309753-B2 | Method for producing optically active cyanohydrin compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20110034718-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034718-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | CBR3, ACSL3, CCNL2 | TSHR 4501/4885KDM4E 1728/4885LMNA 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.